Drug intelligence / Profile preview

V4C-658

Development stage: Preclinical
Lead developer: V4CURE
Modality: Small Molecules

Overview

V4C-658 is a discovery-stage small molecule therapeutic being developed by V4CURE. The compound is part of V4CURE's 'venom-to-cure' platform, which focuses on identifying and optimizing bioactive molecules derived from animal venoms. While specific molecular targets and therapeutic indications for V4C-658 have not been publicly disclosed, it is characterized as a new toxin derivative within the company's early-stage pipeline, leveraging the high specificity and potency inherent in venom-derived chemistry.

Beyond the preview

Go deeper on V4C-658.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V4C-658.

Explore the full profile